Viral Vector-Based Vaccines and Therapeutics
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Attenuated/Inactivated/Live and Vectored Vaccines".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 75
Special Issue Editor
Special Issue Information
Dear Colleagues,
Viral vector technology is at the forefront of medical science, revolutionizing approaches to preventing and treating acute and chronic diseases. Engineered to deliver specific genetic material to cells, these vectors provide a robust platform for vaccine development and gene therapy. This innovative method promises to address unmet medical needs and significantly enhances our ability to respond swiftly to emerging health threats. As we deepen our understanding and improve the design of viral vectors, we set the stage for more precise and effective treatments, potentially transforming the global healthcare landscape.
This Special Issue invites contributions that explore the forefront of viral vector research in both vaccine and therapeutic applications. We seek original research, comprehensive reviews, case studies and perspective pieces that examine the design, development and deployment of viral vector-based solutions. The topics of interest include technological innovations, clinical trial results, safety and efficacy analyses, comparative studies and their impact on global health. We also welcome submissions on developing viral vectors for therapeutic purposes, addressing their potential in treating various diseases. Contributions should consider regulatory, ethical and public perception aspects to foster a multidisciplinary dialogue. This platform allows scholars and clinicians to share insights and propel advancements in viral vector-based vaccines and therapeutics. Join us in shaping the future of research and public health in this dynamic field.
Dr. Sujit Pujhari
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- viral vectors
- vaccine technology
- gene therapy
- immunization strategies
- vector design
- vaccine safety
- vector-based therapeutics
